Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxabact in Primary Hyperoxaluria (ePHex)
NCT03116685Phase 3Completed
- Sponsor
- OxThera AB
- Start
- Jan 2018
- Primary completion
- Apr 2021
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of oxalobacter formigenes in Primary hyperoxaluria (PH), sponsored by OxThera AB. Started Jan 2018; status: completed.
02
Drugs
oxalobacter formigenes
03
Conditions
Primary hyperoxaluria (PH)
Beyond the preview
Go deeper on NCT03116685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03116685.